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Abstract
Introduction: Heparins are common blood anticoagulants that are critical for many
surgical and biomedical procedures used in modern medicine. In contrast to natural heparin derived from porcine gut mucosa, synthetic heparins are homogenous by mass, polymer length, and chemistry.
Materials & methods: Stable cell lines expressing the human and mouse Stabilin receptors were used to evaluate endocytosis of natural and synthetic heparin. We
chemoenzymatically produced synthetic heparin consisting of 12 sugars (dodecamers) containing 14 sulfate groups resulting in a non-3-O sulfated structure (n12mer). Half of the n12mer was modified with a 3-O sulfate on a single
GlcNS sugar producing the 3-O sulfated heparin (12mer). Wildtype (WT), Stabilin-1 knock-out (KO), and Stabilin-2 KO C57BL/6 mice were developed and used
for metabolic studies and provided as a source for primary liver sinusoidal endothelial cells.
Results & conclusions: Human and mouse Stabilin-2 receptors had very similar endocytosis rates of both the 12mer and n12mer, suggesting that they are functionally similar in primary cells. Subcutaneous injections of the n12mer and 12mer
revealed that the 12mer had a much longer half-life in circulation and a higher
accumulation in liver. The n12mer never accumulated in circulation and was readily excreted by the kidneys before liver accumulation could occur. Liver sinusoidal
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endothelial cells from the Stabilin-2 KO mice had lower uptake rates for both dodecamers, whereas, the Stabilin-1 KO mice had lower endocytosis rates for the
12mer than the n12mer. 3-O sulfation of heparin is correlated to both a longer
circulatory half-life and hepatotropism which is largely performed by the Stabilin receptors.
Keywords: Heparin, Liver sinusoidal endothelial cells, Stabilin, Liver, Kidney,
Catabolism

1. Introduction
Heparin is a time-honored anticoagulant [1] for use in multiple therapeutic
treatments including deep-vein thrombosis [2], kidney dialysis [3], venous
thromboembolisms [4], and is used as a key tool to prevent blood coagulation during and after surgery [5]. Heparin is a complex sugar-based polymer composed of N-acetylglucosamine and glucuronic acid/iduronic acid
with multiple sulfation sites [6]. The pattern and density of sulfation determines its affinity for the coagulation factors and other proteins and receptors present in the cardiovascular and reticuloendothelial systems [7]. Hence,
unfractionated heparin (UFH) has the highest affinity for many of the coagulation factors due to the greater average mass of the polymers (mean
mass=13.5 kDa) and its high polydispersity. Low molecular weight heparin
(LMWH) consists of the shorter length polymers (mean size=2.5 kDa) as it
is prepared from the cleavage products of UFH [8]. LMWH is the most common form of heparin in clinical settings as it may be self-administered postsurgically by the patient and available by prescription [9].
The most important modification of heparin for anticoagulation activity
is the 3-O sulfation on N-acetylglucosamine. This sulfation is critical for the
binding of anti-thrombin III [10] and prevents the processing of pro-fibrin
into fibrin. The synthesis of heparin, which has been under development for
the past eight years and is now nearly economically feasible, demonstrates
that the sulfation of the 3-O position of GlcNS has the most impact on heparin’s anticoagulation activity [11–14]. 3-O sulfation is also recognized by
the clearance receptors for heparin and may impact anticoagulation timing and activity [15].
Clearance of systemic heparin is through the reticuloendothelial system
[16] which involves both liver and kidney function. The clearance of UFH involves liver, in contrast to LMWH which is primarily cleared via the kidneys
[17,18]. Patients with renal impairment are subject to increased care and
scrutiny with LMWH administration due to kidney accumulation and bleeding complications that may arise [19–21]. The molecular mechanism of heparin clearance is largely mediated by the Stabilin-2 receptor [22] which is
expressed in liver, spleen, lymph nodes, bone marrow, and in specialized
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structures of the kidney, heart, brain, and eye [23]. Stabilin-2 is a type I receptor and is expressed as two isoforms, a full 315-HARE isoform, and a proteolytically cleaved 190-HARE isoform that retains full functionality as the larger
isoform. Stabilin-2 is a constitutively active receptor that uses the clathrincoat mechanism for rapid internalization with or without ligand [24,25]. Similarly, a close homologue of Stabilin-2, Stabilin-1, is expressed by a wide variety of tissues throughout the vascular and lymphatic systems [26] and may
also participate in heparin clearance within the liver [15,27].
In this report, we demonstrate the use of synthetic homogenous heparin (HS) of a defined size (12mer/dodecamer) and compare two polymers
which do (12mer) or do not (n12mer) contain a single 3-O sulfation on GlcNS
(Fig. 1A) [13,28,29]. These polymers and other similarly sized heparins have
been previously used to determine robust binding and internalization by
both Stabilin-1 and Stabilin-2 receptors [29]. These receptors are similar to
each other [30], though they differ in expression levels, distribution, and affinity for heparin; Stabilin-2 having the highest affinity and higher expression in the liver sinusoids [15,31]. The objectives of this study are to determine the contribution of the 3-O sulfation of the dodecamer (LMWH) in the
clearance of homogenous heparins in a WT mouse model and the contribution of these receptors to heparin cellular endocytosis in knock-out mice.
2. Methods and materials
2.1. Animals
Animals were used in accordance with the Institutional Animal Care and Use
Committee at the University of Nebraska under breeding protocol #1235 and
use protocol #1435. Stabilin-2 knock-out mice were a kind gift from Prof. Atsushi Miyajima at the University of Tokyo and have been previously characterized [32]. The Stabilin-2 knock-out strain was developed in the C57BL/6
background. Stabilin-1 knock-out mice was developed in the C57BL/6 background by Jackson Laboratories using CRISPR/CAS9 technologies to delete
the 2nd exon of the gene to produce a non-productive mRNA (supplemental Fig. 1). Both KO strains are homozygous and phenotypically the same
as reported previously by Schledzewski et al. [27] and verified by the use of
Phire Direct PCR Master Mix (Thermofisher). Male C57BL/6 mice (9–13 weeks
old) were lightly anesthetized with 30% isoflurane mixed with polyethylene
glycol 200 and injected subcutaneously with 100 μL of 35S-labeled heparan
sulfate compound mixed in phosphate buffered saline for a final administration of 0.43 mg/kg body weight. Immediately following injection, the mice
were placed in a metabolic cage containing food and water ad libitum. At
the designated time point, mice were anesthetized with 30% isoflurane and
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Fig. 1. Structure and purity of the dodecamers. A) Schematic representation of the
3-O sulfated (red highlighted modification) and non-3-O sulfated dodecamers used
in this study. B) DEAE-HPLC chromatograms of 12mers. Both 12mers were eluted in
a single peak, indicating that the compounds were pure.
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blood, urine, liver and kidneys were collected. Blood was centrifuged in a Z
serum Sep Clot Activator vacutainer tube (Greiner Bio-one) and 0.1 mL serum was mixed with 4 mL scintillation fluid. Total blood volume was calculated as 7% of body weight by volume. Total urine was collected from both
the cage and mouse and 10% of the volume was mixed with 4 mL scintillation fluid and counted. The remaining 90% of urine and remaining serum
was retained for the degradation assay. Small pieces of liver, approximately
0.1 g, were cut, weighed, and homogenized in 1% NP-40. Kidneys were cut
in half, weighed, and homogenized in 1% NP-40. The homogenized tissues
were centrifuged at 6100×g for 2 min to separate out the solids and the liquid fraction was mixed with 4 mL scintillation fluid and counted.
2.2. Synthesis and purification of the 35S-labeled and biotinylated
dodecamers
S-labeled synthetic n12mer was prepared from the synthetic precursor
12mer without 6-O-sulfate groups, GlcNS-GlcA-(GlcNSIdoA2S)4-GlcNS-GlcApNP synthesized by following the published method [14,33]. The 35S-sulfate was introduced to the 12-mers by heparan sulfate 6-O-sulfotransferases. Briefly, the reaction consisted of 2-(N-morpholino)ethanesulfonic acid
(MES) 50 mM, pH 7.0, 6-O-sulfotransferase 1 (6-OST-1) 0.1 mg/mL, 6-O-sulfotransferase 3 (6-OST-3) 0.1 mg/mL and 2 nmol 35S-labeled 3′-phosphoadenosine 5′-phosphosulfate ([35S]PAPS) (2×107 cpm) and precursor 12mer
(2 mg) in a total volume of 0.5 mL. After incubation at 37 °C for 3 h, the 6-O[35S] sulfo group was incorporated into the 12-mer precursor, but the 6-Osulfation to 12-mer precursor was still incomplete. To this end, an additional
round of 6-O-sulfation using unlabeled PAPS to complete the 6-O-sulfation
step. Here, MES 50mM pH 7.0 buffer, 6-OST-1 0.5 mg, 6-OST-3 0.5 mg, and
30 μmol unlabeled PAPS were add in a total volume of 0.5 mL, then incubated at 37 °C overnight.
HS 12mers with pNP tag (Fig. 1A) (4 mg) and 0.5 mg Pd/C were dissolved in 20mM NaOAc, pH 5.0 in a total volume of 4 mL. Reaction mixture
was vacuumed and refilled with H2 three times. The reaction was then incubated at room temperature for 4 h. It was then filtered to remove charcoal.
The flow through was adjusted to pH 8.5 using 500mM Na2HPO4. Succinimidyl 6-azidohexanoate (8M equivalent of 12mer) was added and incubated at
37 °C overnight. Reaction was purified by DEAE-HPLC column to generate
azido tagged 12mers. PBS (pH 7.4) buffer was bubbled using N2 for 5 min
for preparing the sample solution of 0.1M CuSO4, 0.1M Tris(3-hydroxypropyltriazolylmethyl) amine (THPTA) (Sigma), 0.15M sodium ascorbate, 0.01M
azido tagged 12mer and 0.02M biotin-PEG4-alkyne (Sigma). Mixture of 200
μL THPTA and 40 μL CuSO4 was vortexed, then 80 μL sodium ascorbate, 100
35
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μL 12mer and 100 μL biotin-PEG4-alkyne (from Sigma) was added and bubbled using N2 for 2 min, then incubated at 37 °C overnight. Reaction was purified by DEAE-HPLC column to generate biotinylated 12mers. HPLC and MS
were used to monitor above reactions.
The synthesis of 35S-labeled 12mer was accomplished by converting the
non-3-O sulfated 12mer (n12mer) to 12-mer. The reaction consisted of MES
50mM pH 7.0, 10mM MnCl2, 5mM MgCl2, 3-OST-1 0.1 mg/mL and 1 μmol
PAPS and n12mer (1 mg) in a total volume of 1 mL at 37 °C overnight. Both
n12mer and 12mer were purified by a diethylaminoethyl (DEAE)-HPLC column [29]. Briefly, the DEAE-NPR column (Tosohaas) was eluted with a linear
gradient of NaCl in 20mM sodium acetate buffer (pH 5.0) from 0 to 1M in
60 min at a flow rate of 0.4 mL/ min.
2.3. Isolation and purification of primary liver sinusoidal endothelial cells
(LSECs)
The purification of LSECs has been published previously [34,35]. Briefly, an
anesthetized mouse had its abdomen exposed and portal vein catheterized
with a 24G×0.75 in. catheter and the liver was flushed with phosphate-buffer saline at a flow rate of 4 mL/min. The liver was then digested with Type 1
collagenase (Worthington, Lakewood, NJ) at a concentration of 0.5 mg/mL
in 45 mL for 12 min or until the volume was completely used up. Differential centrifugation separated hepatocytes from non-parenchymal cells and
LSECs were enriched on a 25/50% Percoll gradient, separated from Kupffer
cells by selective adhesion on polystyrene plates, washed and plated in collagen-coated 24-well tissue culture polystyrene plates and allowed a 2 h recovery prior to the experiment.
2.4. Cell lines
Established human Stabilin-2 and Stabilin-1 cell lines are described previously [36]. Briefly, the stab2 cDNA was cloned from human spleen tissue
and the stab1 cDNA was a kind gift from Dr. J. Kzhyshkowska. Both stab
cDNAs were inserted in pcDNA5/FRT/V5/His6-TOPO (Thermofisher) and
named pcDNA5-hStab2 or pcDNA5-hStab1 [15]. The mouse Stabilin-2 cell
line used in these experiments was generated in the same manner and has
not been previously reported. We have compared it with the human Stabilin-2 cell line in terms of both expression level and receptor activity using
a well-established ligand (Supplemental Fig. 2). Stable cell lines were created from 293 Flp-In cells by the transfection of 9.0 μg pOG44 and 1.0 μg
pcDNA5-hStab2 or pcDNA5-hStab1 or pcDNA5-mStab2 (mouse) and 20 μL
Lipofectamine 2000 in a 100mm dish followed by the addition of selection
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media (DMEM+8% FBS+50 μg/mL hygromycin B) 24 h later and stable colonies were selected about 2 weeks post-transfection. Clones were assessed
for recombinant protein expression, normal morphology and were β-gal
negative (for correct insertion within the FRT site in the genome).
2.5. Degradation assay
The collected degraded samples were run through DEAE column following
the procedure described previously [37]. The collected samples were mixed
with 1 mL of 0.01% Triton X-100 buffer at pH 5.0 containing 150mM NaCl,
50mM NaOAc, 3M urea, 1mM ethylenediaminetetraacetic acid (EDTA) before they were transferred to a small DEAE column (200 μL in size). The column was then washed three times with the same buffer, 1 mL each wash.
The column was further washed three times with 0.25M NaCl in 0.001% Triton X-100 buffer, 1 mL each wash. The column was eluted with 1 mL of 2M
NaCl in 0.001% Triton X-100 buffer. The wash flow-through and the eluted
samples were collected and the cpm of 35S was measured by a scintillation
counter. The eluted samples were analyzed by DEAE-HPLC to determine the
elution time of the 35S-labeled peak and compared with the elution time of
intact 12mer.
2.6. Endocytosis assay
Endocytosis assays for the 35S-dodecamers and 125I-streptavidinbiotinylated
dodecamers have been described previously [15,38]. Endocytosis of biotinylated dodecamers was performed with 47 nM 125Istreptavidin pre-mixed
with 190 nM biotinylated dodecamer. The negative control was incubated
with 125I-strepatvidin alone and subtracted from the experimental values to
calculate specific binding/endocytosis. Endocytosis of 35S-dodecamers was
assessed to “test” out the reagent on Stabilin-2 expressing cell lines and
empty vector control cell lines before it was used on animals. In each case,
cells were evaluated in 24-well plates, lysed in 0.3 mL 0.3M NaOH and assessed with a gamma counter for 125I or in a scintillation counter for 35S and
normalized for protein content using the Bradford assay.
2.7. Statistics
The number of animals used in these experiments was at least 5 per time
point and the data was calculated as mean ± standard deviation. Significance was assessed by t-test at a 95% confidence level using SigmaPlot
11.2 software.
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3. Results
The objective of this study was to determine the contribution of the 3-O
sulfate modification of this synthetic LMWH in hepatotropic metabolism. To
do this, we used homogenous chemoenzymatically designed heparan sulfate oligomers that were known to interact with the Stabilin receptors [15].
The size of each oligo is 12 sugars long (dodecamer) consisting of 14 sulfate groups arranged as N- and 6-O sulfated GlcNS and 2-O sulfated iduronic acid. One set of oligos was 3-O sulfated on the 1st GlcNS (3rd sugar)
from the non-reducing end for a total of 15 sulfated groups and is referred
to as the “12mer” in contrast to the “n12mer” which is not 3-O sulfated (Fig.
1A). After the synthesis was complete, each oligo was assessed for purity
by HPLC trace (Fig. 1B). The full characterization of their structure by mass
spectrometry and NMR in addition with their anticoagulant profile against
Factor Xa was previously reported by Xu et al. [29]. Generally, 6-O- [35S]sulfated 12-mers were used for metabolic studies within mice and biotinylated
12-mers were used for cell based assays. The biotin was conjugated to the
reducing end of the terminal GlcA via the p-nitrophenol (pNP) linker (in Fig.
1 biotinylated HS) [39].
To verify that the oligos had similar affinities for the human Stabilin receptors, we performed cell-based endocytosis assays with each new preparation of HS oligo. Similar to previously published experiments [29], the
oligos that we used have a high affinity for 190-HARE cells which are cells
expressing the small isoform of human Stabilin-2 and low affinity for the
parent/empty vector cell line (Fig. 2A). We next compared the affinity of the
biotinylated 12mer (Fig. 2B) and n12mer (Fig. 2C) labeled with 125I-streptavidin with human and mouse Stabilin- 2 and human Stabilin-1 in a comparative study to determine that both human and mouse receptors have
the same binding/endocytosis activity for the ligand. This data is also useful to determine the validity of our animal models with relevance for heparin metabolism in humans. Both Stabilin-1 and Stabilin-2 lines internalized
the oligos with approximately the same rate for 2 h, though accumulation
was greater in the Stabilin-2 line over a 6 h time course than in the Stabilin-1 line (data not shown).
To assess the contribution of the 3-O sulfate modification in heparin metabolism, radiolabeled dodecamers with and without the 3-O sulfation were
subcutaneously injected in mice at a concentration of approximately 0.43
mg/kg, though the molar ratio of polymers that would act against the coagulation factors is higher in homogenously prepared samples than in the
natural heterogeneous LMWH sample. This dose is similar to a standard injection of 40 mg of LMWH in an 80 kg human patient. Immediately after
the injection, individual mice were placed in a metabolic cage for the collection of urine. At each time point, mice were anesthetized and tissues/fluids
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Fig. 2. Internalization of dodecamers in Stabilin expressing cell lines. A) dodecamers labeled directly with 35S were allowed to be internalized by 190- HARE (small
isoform of Stabilin-2) expressing cells and empty vector (EV) cells for 3 h. Cells were
washed, lysed in 0.3 N NaOH and 90% of the lysate was mixed with scintillation
fluid and evaluated by a scintillation counter. The remaining 10% of the lysate was
evaluated for protein content by the Bradford assay. B) Biotinylated 12mer and C)
biotinylated n12mer were conjugated with 125I-streptavidin and incubated with EV,
human Stabilin-1, human Stabilin-2, and mouse Stabilin-2 expressing cell lines for
2 h. Cells were washed 3 times with HBSS, lysed in 0.3 mL 0.3 N NaOH, and evaluated by a gamma counter. Total protein content was evaluated by the Bradford assay. All data presented is the mean ± standard deviation, n = 4.
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Fig. 3. Rates of accumulation of HS dodecasaccharides in tissues. Mice were subcutaneously injected with 35S-12mer or 35S-n12mer and placed in a metabolic cage
until the indicated time point. At the indicated time points, mice were anesthetized
and A) serum, B) urine, C) kidney, and D) liver tissues were collected, weighted, and
assessed for radioactivity. n = 5.

were collected (urine, blood, liver, and kidneys) and assessed for radioactivity and normalized by body weight. The contribution of a single 3-O sulfate made a significant difference in metabolism of these HS dodecamers.
In blood, the amount of 12mer spiked initially and then decreased over time
with a half-life of about 90 min. The n12mer in blood did not show a significant spike and was cleared from blood roughly as soon as it was perfused
in the circulation (Fig. 3A). To determine what had happened to both dodecamers as they were cleared in blood, we obtained urine from the collection cups in the metabolic cages and combined it with any leftover urine in
the bladder at the time of sacrifice. The n12mer rapidly accumulated in urine
in contrast to the slower rate observed with the 12mer which accumulated
slower and then leveled off at the 2 h point (Fig. 3B). The amount of 12mer
in kidney stayed in the range of 0.08–0.11 pmol/mg kidney throughout the
7 h time course of the experiment, in contrast to the n12mer which initially
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Fig. 4. Accumulation ratios for 3-O sulfated and non-3-O sulfated in tissues. The
accumulated radioactivity in either A) urine or B) serum was divided by the liver radioactivity counts at each time point. n = 5.

started out at a high of 0.13 pmol/mg and steadily decreased down to 0.02
pmol/mg (Fig. 3C). The accumulation in liver was quite different, in that the
12mer steadily increased and peaked at 0.31 pmol/mg at 3 h and then decreased steadily to 0.16 pmol/mg by 7 h. This is in contrast to the n12mer
which peaked at only 0.08 pmol/mg within the first 30 min and slowly decreased to near zero over 7 h.
Next, we examined the data as a ratio of both urine to liver and serum
to liver to observe how dynamic the accumulation or clearance of each dodecamer was in relation to the liver. For urine, the amount of n12mer in urine
steadily increased over time in contrast to the 12mer which did not increase
at all—suggesting that the n12mer is not retained within the liver (Fig. 4A).
In serum, the 12mer initially starts very high and decreases at a parabolic
rate to near zero at 7 h. This is in contrast to the n12mer which levels off
early and maintains a low concentration, suggesting that the n12mer clearance is independent of liver activity (Fig. 4B).
Whether the dodecamers are cleared by kidney or liver, they are degraded over the 7 h time course. To determine the amount of degradation
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Fig. 5. Degradation of HS dodecasaccharides in urine and serum. At each time point,
A) serum and B) urine were collected and fractionated over a DEAE column and
counts were assessed by a radiological counter. For serum, each time point is significantly different (p < 0.01) except the last (7 h) time point. For the urine, there was
no significant difference between the HS oligos at all time points (p ≥ 0.05), n = 5.

in either urine or serum, we ran our samples over a DEAE anion exchange
column to separate intact versus degraded polymers. Degraded material
is easily washed off in 0.25M NaCl, whereas, intact polymers have a higher
affinity for the column and only wash off as the column is regenerated in
high salt (2M NaCl). The eluted 12mers from an anion exchange column
with 2M NaCl were analyzed by DEAEHPLC. The DEAE-purified 35S-labeled
component from urine or serum samples showed the same elution profile
on the DEAE-HPLC as that of intact 12mers. The results suggest that the 35Scounts that bound to the anion exchange column represent the undigested
12-mers. Based on the calculation of the ratio of 35S-counts in the wash-off
fractions and the eluted fractions, we estimated the amount of degradation
of 12-mers. The n12mer had a much higher rate of degradation compared
to the 12mer in serum, though both reached the same percentage of degradation by 7 h (Fig. 5A). The percentage of degraded material in urine was
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Fig. 6. Endocytosis of ligands by primary liver sinusoidal endothelial cells (LSECs).
LSECs from WT, Stab1 KO and Stab2 KO mice were purified, plated on collagen, and
allowed to recover for 2 h. Cells were then incubated with either A) 125I-Hyaluronan, B) 125I-SA-b-UFH, C) 125I-SA- 12mer and D) 125I-SA-n12mer for 2.5 h, washed 3
times in HBSS, lysed in 0.3 N NaOH and assessed for radioactivity and protein levels by the Bradford assay. Data are the mean ± standard deviation; n = 3–6. N.S. =
not significant; * p < 0.001 ; # p = 0.011 ; + p = 0.08.

the same for both dodecamers suggesting that clearance mechanisms for
clearing dodecasaccharides in kidney is different from liver (Fig. 5B).
Finally, as liver mediated degradation is performed by the liver sinusoidal endothelial cells (LSECs) and not by other cells within the liver [8,40], we
purified mouse LSECs from WT, Stabilin-1 KO and Stabilin-2 KO mice and
assessed their ability to internalize different ligands. The difference in HA
internalization between the WT and Stab1 KO in contrast to the Stab2KO
mice is expected (p < 0.001) as HA uptake is very specific for the Stabilin-2
receptor (Fig. 6A). In contrast, UFH uptake in in WT and Stab1 KO cells was
nearly identical and was trending less, though not significantly (p=0.08), in
the Stab2 KO cells (Fig. 6B). The statistical difference for n12mer uptake between WT and Stab1 KO cells was not significant though there was a statistical difference between WT and Stab2 KO cells (Fig. 6C). The difference in
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uptake was significantly higher in both Stab1 and Stab2 KO cells when examined for 12mer endocytosis (Fig. 6D) suggesting that the 3-O sulfate on
the HS polymer plays a significant role in the clearance of this molecule via
the Stabilin receptors.
4. Discussion
We have demonstrated that the 3-O modification of a heparin polymer
changes the metabolic route of the molecule. With this modification, the
polymer may bind with coagulation cofactors in the blood and other endothelial cell receptors and molecules to prevent rapid clearance by the kidney. We have also observed that the increased blood residence allows for
increased exposure for binding with the Stabilin receptors which allow the
heparin to be internalized within the liver. In cell culture, 3-O sulfated 12mers
are rapidly taken up by Stabilin expressing cells in contrast to non-3-O sulfated 12mers (this study and [29]). The impact of 3-O sulfation on metabolism is that there is lower accumulation in the kidneys. Although somewhat
controversial, one of the common adverse side-effects of LMWH (enoxaparin and not tinzaparin) is bioaccumulation and bleeding that occurs in patients which may be problematic for individuals with renal disease [41,42].
These dodecamers would be classified as LMWH due to their molecular mass and the 3-O sulfated species has a much higher molar ratio of this
modification than natural LMWH, potentially allowing for a lower dose to
achieve similar bioactivities. Thus, the 12mer is characterized as a heparin
species that has the qualities of both LMWH and UFH. The 12mer:Factor Xa
(FXa) interaction has about half the activity as the UFH:FXa interaction, but
much higher than natural LMWH or Fondaparinux suggesting that the 12mer
may be a good candidate to replace natural LMWH as a prophylactic [29].
A more recent study has shown that a similar dodecamer, the super-12mer
(s12mer), containing 2 3-O sulfation modifications is similar to Enoxaparin
with regards to FXa activity, but is reversible with protamine treatment similar to UFH, thus making it suitable as a heparin analog with enhanced safety
[43]. We would argue that a single 3-O sulfation on a 12mer is not quite as
potent for FXa activity or neutralization by protamine treatment, but shows
us that the contribution of this modification directs the catabolism of the
oligo away from immediate filtration by the kidney. We have compared the
12mer and super 12mer (s12mer), a dodecamer with two 3-O sulfated modifications, with regards to binding and endocytosis in the 315-HARE (Stabilin-2) cell lines using the 35S tracer and found the s12mer is typically slightly
higher in both categories though the difference may or may not be significant, suggesting that these two polymers are nearly identical in recognition
of the Stabilin-2 receptor (Supplemental Fig. 3) [29]. Of course, this is only
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relevant with the Stabilin:oligo interaction and may not directly impact FXa
activity or other coagulation factors.
The binding site for heparin on the Stabilin receptors is not an obvious
string or patch of basic residues and the overall structure for the receptor is
unknown at this time. Binding specificity of heparin is not solely due to their
high negative charge, but also the specificity of the sugar pattern. For example, we already know from previous work heparin may be competed much
better by 4,6-disulfated chondroitin sulfate rather than by 2,6-disulfated
chondroitin sulfate even though the overall charge of both CS polymers
is the same [38]. Here, we propose that the interaction of the 3-O sulfated
GlcNS with the Stabilins has more to do with specificity of this modification within a binding pocket than charge alone. The full-length Stabilin-2
protein has 204 cysteine residues tied up in disulfide linkages and a subset
of these are responsible for the folding of 20 epidermal growth factor domains and one X-Link domain [36]. Hyaluronan binds within the X-link domain and is not competed by heparin [38] nor is the X-link domain even
required for heparin binding [44], unlike the closest homologous XLink domain in TSG-6 [45]. The dodecamers fulfill the requirement for full binding
to the receptor as 10 sugars is the minimum for binding detection [15]. Certainly, the exploration of individual contributions of both Stabilin-1 and Stabilin-2 in the clearance of heparin and other high negatively charged molecules is on-going.
We know that the Stabilin receptors are major clearance receptors for
heparin, but are likely assisted by other receptors on the cell surface. Due to
their charge, heparins are “sticky” molecules and may bind to a multitude of
proteins on the cell surface, but few of those proteins are professional recycling receptors. The Stabilin-2 KO LSECs internalized heterogeneous heparin
(UFH) at nearly the same rate as the WT. This may be due to the presence
of Stabilin-1 in these cells and other receptors that may respond to the lack
of the presence of Stabilin-2. The Stab2KO LSECs had lower internalization
rates of both n12mer and 12mer suggesting that Stabilin-2 has a higher affinity for the HS molecule than Stabilin-1. A single knockout of either Stabilin
receptor did not significantly impact UFH uptake. There may be two explanations for this. First, the remaining Stabilin receptor may serve to compensate for the loss of the companion Stabilin receptor in these cells. Second,
there is a high probability that there are other receptors or molecules on
the surface of the LSEC that may bind with heparins [46]. These may or may
not be professional recycling receptors, but the cumulative effect is significant for heparin metabolism. When we compare our cell lines which are in
the HEK 293 background with LSECs from either mice or rats, the cell lines
are much cleaner and demonstrate lower background binding activity (see
Fig. 2) than the primary cells. This suggests that there are other molecular
factors in the primary cells that work in parallel with the Stabilin receptors.
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In our experiments, we demonstrated that endocytosis of both the n12mer
and 12mer are significantly impacted by Stabilin-2 suggesting that this receptor is a major contributor for heparin clearance.
5. Conclusions
The 3-O sulfation modification of synthetic homogenous heparin increases
half-life in the blood and directs the catabolism to the liver rather than the
kidney. Both Stabilin-1 and Stabilin-2 receptors recognize the 12mer with
higher affinity than the n12mer and the affinity of these ligands for Stabilin-2 exceeds Stabilin-1.
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Supplemental Fig. 1
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Supplemental Fig. 1: Genotype of the Stabilin-1
KO mouse line. This KO mouse line was
developed by Jackson Laboratories in which the
2nd exon of the gene was deleted (dark gray
region) by guide RNAs targeting flanking regions
(green regions). The homozygous deletion in the
mice was verified by PCR (cyan regions). The
image of the gel shows WT parent (+/+),
homozygous KO (-/-), and heterozygous KO (+/-)
with the black arrow indicating the intact exon 2
and red arrow indicating the same amplicon with
the exon 2 deletion. Only homozygous, not
heterozygous Stabilin-1 KO mice were used in this
study.
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Supplemental Fig. 2: Characterization of the mouse Stabilin-2 expressing cell
line. A) 293 Flp-In cells were stably transfected with mouse Stabilin-2 cDNA in
pcDNA5/FRT/V5-6xHis and a clone with similar receptor expression levels to
the human cell line was chosen using the criteria outline in the methods and
materials section. B) Densitometry of the Stabilin-2 receptor in relation to
expression of the housekeeper protein, Vinculin. C) The recombinant mouse
line was compared with the human line for 125I-HA internalization and found
to be nearly identical.
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Supplemental Fig. 3: Endocytosis rates of 12mer and s12mer. Human Stabilin-2 (315HARE) cells were plated in 24-well plates, allowed to grow up to 80% confluency over 2
days and then incubated with a single 3-O-sulfated or double 3-O sulfated dodecamer
over a 2.5 hr time course. At each indicated time point, cells were washed 3x with HBSS
and lysed in 0.3 mL 0.3 N NaOH. Radioactivity was evaluated with a scintiallation counter
and protein was measured by the Bradford assay. n=3, mean±std. deviation.

